Lantheus Holdings, Inc. (LNTH) — SEC Filings
Lantheus Holdings, Inc. (LNTH) — 39 SEC filings. Latest: 10-Q (May 7, 2026). Includes 22 8-K, 7 10-Q, 3 SC 13G/A.
View Lantheus Holdings, Inc. on SEC EDGAR
Overview
Lantheus Holdings, Inc. (LNTH) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Lantheus Holdings, Inc. reported a significant decline in net income for the three and nine months ended September 30, 2025, despite a slight increase in quarterly revenue. Net income for the three months ended September 30, 2025, plummeted to $27.771 million, a substantial 78.8% decrease from $131.
Sentiment Summary
Across 39 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 36 neutral. The dominant filing sentiment for Lantheus Holdings, Inc. is neutral.
Filing Type Overview
Lantheus Holdings, Inc. (LNTH) has filed 7 10-Q, 22 8-K, 2 DEF 14A, 3 SC 13G/A, 2 SC 13G, 1 SC 13D/A, 1 10-K, 1 SC 13D with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (39)
Risk Profile
Risk Assessment: Of LNTH's 27 recent filings, 1 were flagged as high-risk, 13 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $384.014M |
| Net Income | $27.771M |
| Cash Position | $382.006M |
Key Executives
- MaryAnne Heino
- Dr. Brian D. O'Malley
- Dr. Robert E. Smith
- Michael P. Duffy
Industry Context
The radiopharmaceutical and medical imaging industry is characterized by high R&D costs, significant regulatory hurdles, and a trend towards consolidation. Companies are actively pursuing strategic acquisitions to expand their product portfolios and market reach. Lantheus's recent acquisitions align with this industry trend, aiming to bolster its offerings in diagnostic and therapeutic agents.
Top Tags
financials (5) · corporate-governance (5) · regulation-fd (4) · 10-Q (4) · disclosure (4) · compensation (3) · 8-k (3) · Lantheus Holdings (3) · director-changes (2) · acquisition (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Income (Q3 2025) | $27.771M | 78.8% decrease from Q3 2024 |
| Net Income (9M 2025) | $179.471M | 44.7% decrease from 9M 2024 |
| Revenues (Q3 2025) | $384.014M | 1.4% increase from Q3 2024 |
| Revenues (9M 2025) | $1,134.823M | 0.7% decrease from 9M 2024 |
| General & Administrative Expenses (Q3 2025) | $81.898M | More than doubled from Q3 2024 |
| Research & Development Expenses (Q3 2025) | $48.025M | 98.9% increase from Q3 2024 |
| Cash and Cash Equivalents (Sept 30, 2025) | $382.006M | Significant decrease from $912.814M at Dec 31, 2024 |
| Acquisition of Evergreen | $268.933M | Cash outflow for investing activities |
| Acquisition of Life Molecular | $309.011M | Cash outflow for investing activities |
| Repurchase of Common Stock | $200.000M | Cash outflow for financing activities |
| Total Revenue | $350.5M | Increased by 20.8% from $290.1M in Q2 2024 |
| Net Income | $85.2M | Increased by 20.9% from $70.5M in Q2 2024 |
| Other Precision Diagnostics Revenue | $15.5M | Increased from $10.2M in Q2 2024, showing strong segment growth |
| Research and Development Expense | $35.1M | Increased from $30.2M for the six months ended June 30, 2024, indicating continued investment |
| Weighted Average Discount Rate | 10.0% | Used for commercialization milestones, highlighting valuation sensitivity |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Lantheus Holdings, Inc. (LNTH)?
Lantheus Holdings, Inc. has 39 recent SEC filings from Jan 2024 to May 2026, including 22 8-K, 7 10-Q, 3 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of LNTH filings?
Across 39 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 36 neutral. The dominant sentiment is neutral.
Where can I find Lantheus Holdings, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Lantheus Holdings, Inc. (LNTH) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Lantheus Holdings, Inc.?
Key financial highlights from Lantheus Holdings, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for LNTH?
The investment thesis for LNTH includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Lantheus Holdings, Inc.?
Key executives identified across Lantheus Holdings, Inc.'s filings include MaryAnne Heino, Dr. Brian D. O'Malley, Dr. Robert E. Smith, Michael P. Duffy.
What are the main risk factors for Lantheus Holdings, Inc. stock?
Of LNTH's 27 assessed filings, 1 were flagged high-risk, 13 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Lantheus Holdings, Inc.?
Forward guidance and predictions for Lantheus Holdings, Inc. are extracted from SEC filings as they are enriched.